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ABSTRACT 
Worldwide, Campylobacter is one of the leading causes of foodborne bacterial 
gastroenteritis causing an estimated 1.3 million infections in the United States alone. 
Consumption and/or cross-contamination of raw or undercooked poultry products have been 
linked as the most common source of Campylobacter infection, making the poultry industry a 
target for Campylobacter reduction strategies. Campylobacter is prevalent in most poultry flocks 
in the United States, with as many as 90% of flocks Campylobacter-positive at the time of 
slaughter. It is estimated that a reduction of Campylobacter in poultry would greatly reduce the 
risk of campylobacteriosis in humans. Unfortunately, there are a lack of effective intervention 
options to reduce Campylobacter in poultry.  One potential strategy is the use of the natural 
product, chitosan, a deacetylated byproduct of crustacean shells, has been shown to reduce E. 
coli and Salmonella.  The purpose of this study was to determine the ability of chitosan to reduce 
enteric Campylobacter colonization in pre-harvest chickens and on post-harvest chicken skin 
samples.  In each of three trials, 100 birds were divided into 10 treatments (n=10) and were fed 
either 0% (controls), 0.25%, 0.5% or 1% (wt./wt.) of a low, medium or high molecular weight 
chitosan (300 birds total). Birds were fed treated feed for the duration of the study and were 
orally challenged with a four-strain mixture of wild type C. jejuni on day 6. On day 15, the ceca 
were excised and enumerated for Campylobacter. In all three trials, the 0.5% dose of the medium 
molecular weight chitosan reduced cecal Campylobacter counts. Because this medium molecular 
weight chitosan was shown to be the most effective, it was evaluated for post-harvest efficacy 
against Campylobacter on chicken skin.  When a 0.5, 1 or 2% concentration was tested in three 
separate trials, Campylobacter counts were not reduced when compared to controls.  These 
results support the use of chitosan in pre-harvest chickens but not for the reduction of 
 
 
Campylobacter as a post-harvest rinse on skin for the concentrations and strategy used in this 
study.  
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CHAPTER 1: Literature Review 
1.1 Introduction 
Campylobacter spp. is one of the leading bacterial causes of food-borne diarrheal illness 
in the world, causing an estimated 1.3 million infections annually in the United States alone 
(CDC, 2013). According to the European Food Safety Authority (EFSA, 2014), approximately 
nine million food related campylobacteriosis cases occur in the European Union each year. In 
most cases, infection with Campylobacter causes an acute self-limiting gastroenteritis; however 
Campylobacter infections have been associated with more severe, long-term sequelae, including 
Guillain-Barré syndrome (Goodyear et al., 1999; CDC, 2013b), reactive arthritis (Berden et al., 
1979; Ajene et al. 2013), irritable bowel syndrome (NDDIC, 2013), and inflammatory bowel 
disease (CDC 2014).  In many countries, including the U.S., governmental regulatory control 
programs have been implemented to target Campylobacter sources (EFSA, 2010; USDA, 2010; 
FSANZ, 2012). The consumption of poultry products has been identified as the most common 
source of Campylobacter infections  in developed countries (Beery et al., 1988; Rosenquist et al., 
2003; CDC, 2013a), including improperly cooked chicken and cross-contamination from 
handling raw chicken (Danis et al., 2009; Fajó-Pascual et al., 2010; CDC, 2013a). As many as 
90% of U.S. broiler flocks are colonized with Campylobacter (Buzby et al., 1997; Stern et al., 
2001); this can lead to cross-contamination of Campylobacter from the gut contents to the 
surface of the carcass in the processing plant (Hargis et al., 1995; Zhang et al., 2013) and is 
ultimately present on raw poultry products (Moran et al., 2009; Smole Mozina et al., 2009; 
Suzuki and Yamamoto, 2009). Campylobacter jejuni is the most common species identified in 
cases of food-borne campylobacteriosis (Friedman et al., 2000).  
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1.2 Characteristics of Campylobacter 
1.2.1 History and discovery 
Theodore Escherich first observed and described Campylobacter in 1886, noting a spiral-
shaped and non-culturable bacteria (Escherich, 1886), and it was later isolated from aborted 
bovine fetuses by McFadyean and Stockman in the early 1900s (Skirrow, 2006). Over the next 
few decades, similar bacteria were isolated from the feces of cattle and pigs with diarrhea, which 
were initially classified as Vibrio jejuni and Vibrio coli, respectively (Jones et al., 1931; Doyle 
1944). Later, in 1963, Sebald and Véron separated Campylobacter from the genus Vibrio and 
proposed a new Genus, Campylobacter. Campylobacter differs from Vibrio in their genomic 
characteristics (guanine-cytosine content for Campylobacter is between 29-36%, whereas G-C 
content for Vibrio is 40-50%), their characteristic non-fermentive metabolism and fastidious 
growth requirements (Sebald and Véron, 1963; Véron and Chatelain, 1973). The Genus 
Campylobacter is classified under the family Campylobacteriaceae, which also includes 
Arcobacter, Helicobacter, Sulfospirillum and Wolinella (Lee and Newell, 2006; Debryne et al., 
2008). In 1973, additional organisms originally identified as Vibrio-like microaerophilic bacteria 
were classified under the genus Campylobacter, including C. jejuni and C. coli (Véron and 
Chatelain, 1973; Butzler, 2004). 
1.2.2 Morphology 
Campylobacter is derived from two Greek words, “kampulos” and “bacter”, meaning 
“curved” and “rod”, respectively (Sebald and Véron, 1963). The organisms in the family 
Campylobacteraceae are generally small, Gram negative, slender rods, ranging in size from 0.2-
0.9 µm in width and 0.5-5 µm in length (Peterson, 1994; Debryne et al., 2008; Senok and Botta, 
2009). Campylobacters are non-spore forming and contain single polar flagellum at one or both 
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ends, allowing them to be highly motile (Debryne et al., 2008; Silva et al., 2011). Multiple cells 
may group together, forming an “S” or “V” shape, visible under a microscope (Silva et al., 2011) 
1.2.3 In vitro growth requirements and VBNC form 
Campylobacter spp. require complex growth media for in vitro growth (Buck and Smith, 
1986; Kelly, 2001). C. jejuni and C. coli are capable of growing at temperatures between 30 and 
42°C, with 42°C being the optimum growth temperature (Nachamkin, 1995; Park, 2002; Silva et 
al., 2011). In addition, these organisms require microaerophilic growth conditions of a reduced 
oxygen atmosphere containing 5% O2, 10% CO2, and 85% N2 (Park, 2002; Garénaux et al., 
2008). Campylobacter spp. are fastidious and sensitive to fluctuating oxygen levels, freezing, 
salinity, moisture availability, acidic conditions (pH ≤5.0), and temperature (Altekruse et al., 
1999; Park, 2002). 
It has been proposed that Campylobacter spp. can survive in adverse conditions by 
converting to a viable but non-culturable (VBNC) state, in which the organism enters a 
physiological state that may be difficult or impossible to detect, but certain core metabolic and 
cellular processes still function (Portner et al., 2007). It has been suggested that these VBNC 
cells are still capable of infecting hosts (Saha and Sanyal, 1991), although the role of the VBNC 
state in microbial organisms is still unclear (Pinto et al., 2013).  
1.2.4 Environmental reservoirs of Campylobacter 
Campylobacter spp. are most often found in warm-blooded animals, including many food 
animal sources, such as chickens, pigs, turkeys, lamb, cattle, dairy cows and duck (Nesbakken et 
al., 2003; Humphrey et al., 2007; Lin et al., 2007). Untreated water is also considered a 
consumption risk for humans (Schorr et al., 1994; Eberhart-Phillips et al., 1997; Friedman et al., 
2004), as is raw milk, which has also been established as a route for Campylobacter, resulting in 
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human gastroenteritis (Blaser et al., 1979; Robinson et al., 1979; Porter and Reid, 1980; Potter et 
al., 1983). In addition to animal food sources, water and unpasteurized milk, contact with farm 
animals and domestic pets also increase the risk of Campylobacter colonization and infection 
(Kapperud et al., 1992; Saeed et al., 1993; Schorr et al., 1994; Studahl and Andersson; 2000). 
Poultry have been established as a common Campylobacter reservoir. In addition to 
horizontal transmission from coprophagic behavior of poultry, there are many other vectors 
which serve as a source for Campylobacter in poultry (Shane, 1992). High flock concentrations, 
as well as cross-contamination from litter, fecal contact, farm personnel and other animals may 
aid in dissemination, while environmental water supplies, insects, wild birds and rodents also 
increase the risk of Campylobacter spp. colonization (Aarts et al., 1995; Line et al., 2001; Adkin 
et al., 2006; Horrocks et al., 2009). 
1.3 Campylobacteriosis in humans 
It has been established that Campylobacter spp. are capable of causing infections in 
animals since the early 1900s; however, it wasn’t until about 1980 that Campylobacter spp. were 
identified as causing disease in humans (Silva et al., 2011). In recent years, it has been 
acknowledged that Campylobacter spp. is the most common bacterial agent causing enteritis in 
the world (Skovgaard, 2007) and consumption of poultry meat has been reported as the most 
common cause of campylobacteriosis in humans (Silva et al., 2011). Numerous other studies 
have also reported that improper handling and/or consumption of undercooked poultry or poultry 
products are a significant source of campylobacteriosis in humans (Beery et al., 1988; Butzler 
and Oosterom, 1991; Tauxe, 1992; Tauxe, 1997; Corry and Atabay, 2001; Nadeau et al., 2002; 
CDC, 2013a). Campylobacter spp. are responsible for infections in both industrialized and 
developing countries, and tend to cause more infections in children, immunocompromised, and 
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elderly persons (Tauxe 1992; Nachamkin and Skirrow, 1998; Corry and Atabay, 2001). Based on 
reports by the European Food Safety Authority and the European Centre for Disease Prevention 
and Control, campylobacteriosis is the most commonly reported zoonotic disease in the 
European Union; the second is salmonellosis (EFSA, 2014). In 2006, the United States reported 
43,696 cases of campylobacteriosis, and it is estimated that the true value of this number should 
be approximately 845,024 cases, when considering under-reporting and under-diagnosing 
patients (Scallan et al., 2011). In addition, 80% of these cases confirmed were declared food-
borne (Scallan et al., 2011). A surveillance study completed in England and Wales showed that 
C. jejuni caused at least 12 times the number of confirmed campylobacteriosis cases than C. coli 
(Friedman et al., 2000). Treatment for campylobacteriosis is often expensive and in 1994, it was 
estimated that the average cost to treat a Campylobacter spp. infection was roughly $920 per 
case (CAST, 1994). As of 2010, it is estimated that treatment for campylobacteriosis is $1,846 
per case (Scharff, 2012), equating to detrimental economic costs of approximately $1.6-1.7 
billion annually (Batz et al., 2012; Hoffmann et al., 2012; Scharff, 2012).  
1.3.1 Mechanisms of pathogenesis 
Pathogenic mechanisms of Campylobacter spp. are still not fully known or understood. It 
has been proposed that adhesion and invasion of intestinal epithelium may play a role in 
producing the symptoms associated with campylobacteriosis. Potential virulence factors, 
including flagella-driven motility, invasive mechanisms, adherence within in the mucosa, and 
toxin production, have been identified and are believed to be part of Campylobacter spp. 
pathogenesis (van Vliet and Ketley, 2001; Asakura et al., 2007; Dastia et al., 2010).C. jejuni 
polar flagellum is comprised of two part system: a sensor (FlgS) and a response regulator (FlgR), 
that aid in the flagellum function (Dastia et al., 2010). Cytolethal distending toxin genes (cdt 
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genes) have been sequenced for C. jejuni (Pickett et al., 1996; Bang et al., 2001), as well as C. 
coli and C. fetus (Asakura et al., 2007; Asakura et al., 2008). These genes are responsible for 
preventing eukaryotic cells from entering into the mitosis phase, ultimately causing cell death 
(Yamasaki et al., 2006; Ge et al., 2008; Zilbauer et al., 2008). 
1.3.2 Acute infection 
Campylobacter is the most common cause of diarrheal illness in humans (CDC, 2013a) 
and common symptoms of campylobacteriosis include fever, nausea, general malaise, watery or 
bloody diarrhea, vomiting, and severe abdominal pain (Allos and Blaser, 1995; Rosenquist et al., 
2003; Butzler, 2004). These symptoms generally last between 1 to 11 days, and the diarrhea is 
self-limiting in most cases (Allos and Blaser, 1995; Rosenquist et al., 2003). Campylobacter spp. 
infections can be caused by as few as 500 cells (Robinson, 1981). 
1.3.3 Long-term complications 
Infection with Campylobacter has been linked with serious post-infectious complications, 
such as Guillain-Barré syndrome, reactive arthritis, irritable bowel syndrome and inflammatory 
bowel disease.  
1.3.3.1 Guillain-Barré syndrome 
One potential long-term complication is Guillain-Barré syndrome, a severe, but relatively 
rare, syndrome that appears in roughly 1 in 1000 Campylobacter cases (Buzby et al., 1997; CDC, 
2010b). Guillain-Barré syndrome is a neuromuscular disorder, which results in weakness of the 
limbs and respiratory muscles, as well as loss of reflexes (Mishu and Blaser, 1993; Mishu et al., 
1993; Allos, 1997). Guillain-Barré syndrome usually starts with rapid onset of symptoms, with 
weakness progressing over a period of one to four weeks, while recovery generally takes many 
months following treatment (Ropper et al., 1991). Outcomes of Guillain-Barré vary and while 
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some patients are permanently paralyzed or wheelchair-bound, many recover with only minor 
long-term symptoms (Buzby et al., 1997). In 5-10% cases, Guillain-Barré syndrome can be fatal 
and death may occur due to respiratory paralysis (Kuwabara, 2004; Willison, 2005). A similar 
syndrome, called Miller-Fisher Syndrome, a variant of Guillain-Barré syndrome has been 
reported, which is characterized by symptoms such as opthalmolplegia (paralysis of the eye 
mucles), areflexia (lack of neurological reflexes), and ataxia (lack of coordinated muscle 
movements) (Othsuka et al., 1988;Kuwubara, 2004) 
1.3.3.2 Reactive Arthritis 
Reactive arthritis (ReA), or post-infectious arthritis, is a disease defined by joint and 
tissue inflammation, which occurs subsequent to bacterial gastrointestinal infections, including 
Campylobacter (Wu and Schwartz, 2008; Carter, 2006; Carter and Hudson, 2009; Townes, 
2010).  Reportedly, 1-5% of Campylobacter cases may result in reactive arthritis (Pope et al., 
2007), including symptoms such as joint inflammation, inflammation of eyes, skin or tendons 
(Pope et al., 2007; Townes, 2010). Reactive arthritis can either be self-limiting (6 months or less) 
or chronic (Carter, 2006). Diagnosis of reactive arthritis is subjective and currently there are no 
established diagnostic tests for reactive arthritis (Sieper et al., 2002; Ajene et al., 2013). Reactive 
arthritis is not gender-dependent, but is more common in adults than children (Carter, 2006).  
1.3.3.3 Irritable Bowel Syndrome 
Irritable bowel syndrome (IBS) is a gastrointestinal disorder and is broadly generalized 
by frequent abdominal pain (more than three times per month) over repeated months (three or 
more) that cannot be due to any other disease (NDDIC, 2013). Common symptoms include 
general abdominal discomfort, more or less frequent bowel movements, abnormal stool (too 
loose or too hard), passing mucus and abdominal bloating (NDDIC, 2013). The link between 
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Campylobacter and IBS is not fully understood and the relationship between the two is 
continually changing (Riddle et al., 2012). According to Pimentel et al. (2008), mice have 
provided a model linking C. jejuni infections to overgrowth of bacteria in the small intestine, GI 
motor dysfunction and chronic inflammation. 
1.3.3.4 Inflammatory Bowel Disease 
Inflammatory bowel disease (IBD) is a broad category, and is used to describe chronic or 
recurring inflammatory responses of the gastrointestinal tract (CDC 2014). IBD encompasses 
multiple diseases, including ulcerative colitis and Crohn’s disease (CDC 2014), chronic 
inflammatory diseases which are distinct from IBS. Food-borne pathogens, including E. coli, M. 
avium, Salmonella and C. jejuni are all suspected pathogens that may be linked to IBD 
(Darfeuille-Michaud et al., 1998; Boudeau et al., 1999; Sartor, 2003; Gradel et al., 2009). No 
medical cure currently exists and patients must manage with this chronic disease for their 
lifetime (CDC 2014). 
1.4 Campylobacter in poultry 
1.4.1 Campylobacter in retail poultry products 
Research has shown that retail poultry products have much variability in regards to the 
presence or absence of Campylobacter contamination. A study by Zhao et al. (2001) found 
70.7% of retail chicken meat samples to be contaminated with Campylobacter during a 14-month 
study of four major supermarket chain stores. A majority of these samples were identified as C. 
jejuni, with the remaining being C. coli or “other” Campylobacter spp. (Zhao et al., 2001). More 
recent studies and reports have suggested that 90-100% of raw chicken meat is contaminated 
(Moran et al., 2009; Smole Mozina et al., 2009; Suzuki and Yamamoto, 2009; EFSA, 2014). 
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Another study looked at antibacterial resistance of Campylobacter spp. recovered from 
retail meat, finding 94% of the samples to be resistant to at least one or more of the seven 
antimicrobials tested, which included tetracycline (82% resistant), doxycycline (77%), 
erythromycin (54%), nalidixic acid (41%), ciprofloxacin (35%), chloramphenicol (1%) and 
gentamicin (0%) (Ge et al., 2003). 
1.4.2 Campylobacter colonization in birds 
While Campylobacter infection in humans causes adverse reactions, Campylobacter spp. 
colonize the intestinal tract of poultry asymptomatically around 2-3 weeks of age, as a 
commensal organism (Beery et al., 1988). Avian bodies provide an ideal growing environment 
for Campylobacter spp., including an optimum growth temperature (Luechtefeld et al., 1980; 
Kapperud and Rosef, 1983; Altekruse et al., 1999). Campylobacter is commonly isolated from 
the lower intestines, predominantly from the ceca, and concentrations may reach up to 108 
colony forming units (CFU) per gram of cecal content (Beery et al., 1988; Newell et al., 2000; 
Cole et al., 2006). Previous studies have shown that Campylobacter spp. are present in poultry 
year-round, and present a specific concern during the warmer months (between May and 
October) (Willis and Murray, 1997; Nylen et al., 2002). During summer months samples tested 
positive for C. jejuni in 87-97% of those evaluated (Willis and Murray, 1997) and other studies 
reflect similar findings (Stern and Line, 1991; Zhao et al., 2001). It is estimated that between 40-
70% of poultry flocks in the EU are Campylobacter-positive at time of slaughter (Denis et al., 
2001; Herman et al., 2003; Reich et al., 2008), while in the United States, as many as 90% of 
flocks are Campylobacter-positive at time of slaughter (Buzby, et al. 1997; Stern et al., 2001). 
1.4.3 Horizontal transmission 
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Horizontal transmission is the widely accepted mode of transmission of Campylobacter 
in poultry (Carrillo et al., 2005; Horrocks et al., 2009; Silva et al., 2011). Natural colonization of 
commercial poultry generally occurs around 2-3 weeks of age, and birds begin shedding 
Campylobacter in the feces (Mead, 2002).  It has been observed that Campylobacter spp. spread 
quickly from bird to bird and can rapidly colonize an entire flock (Carrillo et al., 2005; Horrocks 
et al., 2009). This is aided by birds’ coprophagic tendencies, in which Campylobacter spp. are 
disseminated via the fecal-oral route (Keener et al., 2004). Once internalized by the bird, a study 
by Cox and colleagues demonstrated rapid dissemination and long-term persistence in lymphoid 
organs after intra-cloacal or oral inoculation of C. jejuni in day-old broiler chicks (Cox et al., 
2005). 
1.4.4    Vertical Transmission 
A more debated source of contamination is vertical transmission, in which 
Campylobacter spp. are passed from breeding flock hens to hatched eggs (Silva et al., 2011). 
Campylobacter spp. have been detected in eggs and hatchery fluff, further indicating the 
possibility of vertical transmission (Silva et al., 2011). Cox and colleagues (2012) discuss the 
high likelihood that vertical transmission as a source of Campylobacter contamination, citing 
previous research that focused on evidence of transmission from breeder hens to broiler 
offspring, after identifying indistinguishable Campylobacter isolates in both groups (Cox et al., 
2002). More research is needed to determine whether vertical transmission is a likely source of 
Campylobacter contamination. 
1.4.5 USDA regulations 
In 2010, the United States Department of Agriculture Food Safety and Inspection Service 
(FSIS) initiated the implementation of Campylobacter monitoring and control for chickens and 
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turkeys (USDA, 2010). Performance standards for chickens require that no more than 10.4% (of 
1 mL samples) or 46.7% (of 30 mL samples) be positive for Campylobacter for processing plants 
to pass. Performance standards for young turkeys require that no more than 3 of 56 samples be 
positive for Campylobacter (USDA, 2010). The accompanying compliance guide included pre-
harvest strategies aimed at reducing Campylobacter, with hopes of drastically reducing 
Campylobacter cases within two years (USDA, 2010). Campylobacter spp. reporting actively 
continues through FoodNet (Foodborne Diseases Active Surveillance Network) (Scallan et al., 
2011). 
1.5 Pre-harvest poultry intervention strategies 
The development of intervention strategies is important to the control and reduction of 
Campylobacter in poultry to reduce the human risk. A risk model developed by Rosenquist and 
colleagues (2003) predicted that a 2-log reduction of Campylobacter in poultry can reduce 
human infections by 30 times. Many pre-harvest strategies have been evaluated, including 
biosecurity, probiotics and competitive exclusion, bacteriocins, bacteriophages, vaccines and 
natural compounds, including medium chain fatty acids and plant extracts with varying results. 
1.5.1 Biosecurity 
In the last decade the necessity of biosecurity has increased, especially considering the 
regulatory measures implemented by the USDA. With many potential vectors for contamination, 
including, but not limited to, feed, water, litter, insects, air, farm personnel, and cross-
contamination of feces, modified hygienic barriers have become necessary on poultry farms 
(Newell et al., 2011; Silva et al., 2011). A review of Campylobacter interventions by Newell and 
colleagues (Newell et al., 2011) concluded that while the determined risk levels for some factors 
are unknown, visitors and farm personnel pose a high risk as a transport route for Campylobacter 
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spp. Many companies and farms have implemented biosecurity hygiene barriers including hand-
sanitizing and requiring boots and coveralls upon farm entrance (Silva et al., 2011). In addition, 
equipment, vehicles and temporary machinery may also contaminate farms, if not properly 
decontaminated prior to arrival (Newell et al., 2011). While many of these hygienic procedures 
are not strictly adhered to (Silva et al., 2011), it has been demonstrated that diligent application 
of basic biosecurity (i.e. boots, coveralls, foot baths) may reduce flock colonization (Kiess et al., 
2007). 
1.5.2 Probiotics and competitive exclusion 
Probiotics are non-pathogenic organisms that can be applied singularly, but are often 
combined as a mixture, and colonize with the gastrointestinal tract to improve gut health (Fuller 
1989; Vanbelle et al., 1990; Griggs and Jacob, 2005). In poultry research, probiotics are 
generally administered to day-of-hatch chicks, with the purpose of allowing beneficial probiotic 
bacteria to colonize the gastrointestinal tract prior to contact with pathogenic organisms in the 
gut (Aguiar et al, 2013). This concept is called competitive exclusion (Mead, 2002), introduced 
by researchers Nurmi and Rantala in 1973, while studying Salmonella in broilers (Nurmi and 
Rantala, 1973). While efficacy has been shown for Salmonella control, inconsistencies have been 
noted when aimed at Campylobacter (Shanker et al., 1990; Mead, 2002; Bielke et al., 2003; 
Bhaskaran et al., 2011; Aguiar et al. 2013). Previous research has shown mixed efficacy, but 
studies have reported a reduction of C. jejuni when birds were administered L. acidophilus and 
Enterococcus faecium (Morishita et al., 1997), and B. subtilis spp. (Aguiar et al., 2013). 
1.5.3 Bacteriocins 
Bacteriocins are anti-bacterial proteins or peptides, produced by bacteria, and are capable 
of killing or inhibiting the growth of other closely related bacteria (Cleveland et al., 2001). 
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Limited research is available concerning bacteriocins in relation to Campylobacter spp. 
inhibition, but it has been acknowledged that further research is warranted (Stern et al., 2005). A 
study by Cole et al. (2006) showed the significant reductions of cecal Campylobacter in turkey 
poults using two orally administered bacteriocins, isolated from P. polymyxa and L. salivarius. In 
three separate trials, these bacteriocins reduced Campylobacter to non-detectible levels in 
comparison to the positive controls, all of which were orally challenged with approximately 105-
106 CFU/mL C. coli mixture (Cole et al., 2006). Additional studies utilizing bacteriocins 
produced by P. polymyxa, L. salivarius, E. durrans/faecium/hirae, and E. faecium have showed 
similar results of non-detectible levels, which range from 2.2-6.6 log reductions in chickens  
(Stern et al., 2005; Svetock et al., 2005; Stern et al., 2006; Line, et al. 2008; Svetock et al., 2008). 
While bacteriocins present a potential effective solution, worthy of future research, bacteriocins 
may be limited in application (Lin, 2009). They are expensive and current regulatory issues 
would prevent industry-wide application. In addition, it has been proposed that Campylobacter 
spp. could develop resistance to bacteriocins and this should be determined prior to 
implementing bacteriocins as an intervention strategy (Hoang et al., 2011). 
1.5.4 Bacteriophages 
Bacteriophages are viruses capable of infecting and killing targeted bacteria (Huff et al., 
2005). Campylobacter-specific phages have been recovered post-harvest in chilled retail poultry, 
proving capable of surviving further processing conditions (Atterbury et al., 2003). Two Listeria 
bacteriophage products are currently approved by the FDA and utilized in the food production 
industry, one for ready-to-eat foods (Bren, 2007) and another for meat and cheese products 
(Carlton et al., 2005). Targeted Campylobacter phages have been isolated from broiler and layer 
chicken excreta, retail poultry and other animal sources (Connerton et al., 2011). Bacteriophages 
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specific for C. jejuni have been administered to chicks, resulting in 0.5-5 log reductions of cecal 
Campylobacter (Carrillo et al., 2005). A bacteriophage cocktail containing three phages 
administered to chickens reduced Campylobacter by 2 logs, a result seen throughout the trial 
duration (Carvalho et al., 2010). In comparison, another study did not find reduction of 
Campylobacter jejuni or coli using two Campylobacter-targeted phages (Orquera et al., 2012). 
More research is needed for bacteriophage application as there are concerns about the 
development of phage resistance in vitro and in vivo (Lu and Koeris, 2011). Bacteria are capable 
of acquiring resistance to bacteriophages, making bacteriophages unlikely as an independent 
solution to Campylobacter, but potentially as a multifaceted reduction strategy (Carrillo et al., 
2005). 
1.5.5 Vaccination 
Another route investigated to reduce or eliminate Campylobacter is by developing 
vaccines, which overall have had limited success. Previous researchers have noted the difficulty 
of vaccine efficacy in poultry, most likely due to the commensal interaction of Campylobacter in 
the poultry gut (Rice et al., 1997; de Zoete et al., 2007). In addition, a Campylobacter vaccine 
has been challenging to develop due to the difficulty of identifying specific antigens (Saxena et 
al., 2013). Baqar and colleagues (1995) tested two killed Campylobacter vaccines in monkeys, 
finding that a mucosal adjuvant played an important role in its potential efficacy, warranting 
future research. A research group compared two commercially available Campylobacter 
vaccines, containing C. fetus subsp. fetus and C. jejuni strains, in guinea pigs (Burrough et al., 
2010). Results from this study suggested that an autogenous vaccine may be effective in 
reducing the Campylobacter strain used in the study. Recent vaccine attempts have had mixed 
success, but a commercial vaccine for poultry has still not been produced (Buckley et al., 2010; 
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Clavero, 2013). Vaccines are still being researched and would provide an ideal method of control 
if applicable at the hatchery stage prior to rearing and processing. 
1.5.6 Natural compounds 
In recent years, there has been consumer emphasis on the demand for safe, natural food 
products that are free of synthetic residues (Xu et al., 2008). Natural products, generally widely 
present in nature, inexpensive and many of which are considered GRAS (Generally Recognized 
As Safe) by USDA, have been shown to possess antimicrobial properties (Chaveerach et al., 
2002; Friedman et al., 2002). 
1.5.6.1 Medium chain fatty acids 
Caprylic acid, along with other fatty acids, has been found to possess antimicrobial 
properties against an array of bacteria (Petschow et al., 1996; Sprong et al., 2001; Vasudevan et 
al., 2005). Caprylic acid, a medium-chain fatty acid comprised of eight carbons, is naturally 
found in coconut oil, bovine and breast milk (Jensen et al., 1990; Jensen, 2002; Nair et al., 2005). 
Studies by Solis de los Santos et al. (2008a, b) have shown that varying doses of caprylic acid are 
capable of reducing C. jejuni prophylactically and therapeutically. 
1.5.6.2 Plant extracts 
Plant extracts have been evaluated for antibacterial properties, especially as there is 
increased pressure to shift away from antibiotic use in animals (Atterbury et al., 2003; Sirsat et 
al., 2009). Rosemary and rosemary extract both possess antioxidant activity and also show anti-
Campylobacter potential (Klančnik et al., 2009). A study by Murali et al. (2012) evaluated the 
efficacy of multiple plant extracts and teas against C. jejuni. Lemon extract, turmeric extract, 
roobios tea, mint tea and green tea were all capable of inhibiting C. jejuni in pre-chilled and post-
chilled carcasses, as well as retail chicken meat within 36 hours of incubation (Murali et al., 
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2012). Tran-cinnamaldehyde, eugenol, carvacrol, thymol and cranberry extract have also been 
evaluated and have shown mixed efficacy against Campylobacter spp. (Metcalf, 2008; Arsi, 
2011; Woo-Ming, 2012).  
1.6 Post-harvest poultry intervention strategies 
Pre-harvest intervention strategies have not been effective at consistently reducing or 
eliminating Campylobacter at the farm level, therefore Campylobacter remains a challenge 
during processing and post-harvest, in which these organisms are capable of cross-contaminating 
other carcasses and equipment in the plant (Hargis et al., 1995; Byrd et al., 1998; Corrier et al., 
1999; Zhang et al., 2013). Processing plants provide for potential increases and decreases in 
bacterial load. Previous studies have shown counts multiplying between 10 and 1,000 times 
between the farm and the plant, de-feathering or evisceration (Acuff et al., 1986; Izat et al., 1988; 
Stern et al., 1995). A study by Melero et al. (2012) followed two flocks, from farm to the product 
packaging in stores and measured Campylobacter prevalence at five points: on the farm, 
slaughter, deboning, processing and product packaging. For Farm A, Campylobacter was present 
at 89%, 70%, 100%, 69% and 59%, respectively, while for Farm B, Campylobacter was present 
at 44%, 96%, 63%, 69% and 69% during the five stages (Melero et al., 2012). Campylobacter 
spp. are generally environmentally sensitive and while chilled storage (at 4ºC) doesn’t appear to 
considerably reduce bacteria load (Simmons and Gibbs, 1979; Blankenship and Craven, 1982; 
Oosterom et al., 1983a; Yogasundram and Shane, 1986), freezing products (at -20ºC) is capable 
of reducing the Campylobacter load by 0.5-2.5 logs (Hänninen, 1981; Oosterom et al., 1983b; 
Yogasundram and Shane, 1986). Once departing the processing plant, packaged poultry meat is 
still a significant source of Campylobacter jejuni (Harris et al., 1986; Altekruse et al., 1994), 
making post-harvest intervention a key step in Campylobacter reduction. Previous studies have 
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investigated salt solutions and antibacterial agents, including trisodium phosphate, as potential 
carcass sprays to reduce Campylobacter (Slavik et al., 1994). Natural compounds previously 
mentioned, including medium chain fatty acids and plant extracts, may be potentially efficacious 
as post-harvest interventions, applicable in poultry processing plant systems. Post-harvest 
applications must also take into account challenges with palatability, texture and odor alterations 
that may occur after application (Goode et al., 2003). 
1.7 Chitosan  
1.7.1    Overview of chitosan 
Chitosan is a natural biopolyaminosaccharide produced by deacetylation of chitin, more 
commonly recognized as crustacean shell waste from crab, lobster, shrimp and other species (No 
and Meyers, 1995; Qin et al., 2006). Chitosan is produced commercially, deacetylated at 
different degrees (usually 40-98%) (Ravi Kumar, 2000) and varies in molecular weight (No and 
Meyers, 1995; Genta et al., 1998). According to No et al. (2007), chitosan is the “second most 
abundant natural biopolymer”, following cellulose, making it available it large quantities and, 
ideally, inexpensive (Rabea et al., 2003; Qin et al., 2006), as well as biodegradable, non-toxic 
and biocompatible (Rinaudo, 2007). Unmodified chitosan is insoluble in water (Rabea et al., 
2003; Qin et al., 2006) and tends to coagulate or come out of solution completely at higher pH 
levels (pH > 6.5) (Rabea et al., 2003). Chitosan is soluble in organic acids, including acetic acid 
(Rabea et al., 2003), and increases in viscosity as concentration increases. Chitosan isn’t a novel 
natural productas it has been previously applied in commercial industry practices, including 
biomedical, food production, pharmaceutical, and chemical sectors (Muzzarelli, 1977; Knorr, 
1984; Chung and Chen, 2008). Because of the chelating properties of chitosan, it has been 
applied in waste water treatment (No and Meyers, 2000). Its anti-inflammatory, hemostatic, 
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antitumor, antioxidant, antimicrobial and immunostimulatory properties (Park et al., 2011) make 
it an ideal potential applicant for further biomedical research. 
1.7.2 Mechanism of action 
The antimicrobial mode of action of chitosan (as well as chitin and other derivatives) is 
largely unknown (Rabea et al., 2003; Raafat et al., 2008). A study by Rabea and colleagues 
(2003) observed chitosan primarily acting on the outer membrane of bacteria, concluding that 
chitosan is capable altering cell permeability (Rabea et al., 2003). Previous research has 
indicated that chitosan is a chelating agent (Muzzarelli et al., 1980; No and Meyers, 2000) and 
may be capable of binding trace metals, therefore inhibiting toxin production or microbial 
growth (Cuero et al., 1991), as well as fats, cholesterol and proteins (No and Meyers, 2000). 
Chitosan is not soluble in water, but is soluble in many acids, including acetic, formic, 
lactic, ascorbic, tartaric and propionic acids (Piskin et al., 1986; No et al., 2002). The acidic 
medium may be key for chitosan to have an antimicrobial effect (Rabea et al., 2003; Qin et al., 
2006).  
1.7.3 Chitosan research 
Chitosan possesses promising antibacterial potential, as a natural product with a broad 
killing spectrum and low toxicity to mammalian cells (Franklin and Snow, 1981; Takemono, 
1989; Liu et al., 2001). Chitosan has demonstrated efficacy against other Gram- positive and 
negative organisms, as well as fungi, including E. coli, Salmonella, Pseudomonas and 
Campylobacter (El Ghaouth et al., 1992b; Laflamme et al., 2000; Ganan et al., 2009; Friedman 
and Juneja, 2010). Ganan and colleagues (2009) analyzed the efficacy of three different 
molecular weight chitosans (120, 400 and 643 kDa) individually on 3 strains of C. jejuni and 1 
strain of C. coli. The C. coli strain was reduced to undetectable levels (1.48 CFU/mL) compared 
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to the control (median log of 6.3 CFU/mL) by all three chitosans at a concentration of 0.05% 
(Ganan et al., 2009). The three C. jejuni strains were reduced to undetectable levels compared to 
the controls (median log 8.23-9.09 CFU/mL) by the 120 and 400 kDa chitosans, and 
significantly reduced by the 643 kDa chitosan at a concentration of 0.05% (Ganan et al., 2009). 
Another group studied the efficacy of chitosan against S. aureus, finding a concentration of 1-
1.5% necessary to completely inactivate this bacterium (Wang et al., 1992). E. coli inhibition 
was possible with concentrations of 0.5-1% chitosan, and could be completely inactivated with 
concentrations greater that 1% (Wang et al., 1992). Chitosan has displayed anti-fungal properties 
in corn and peanut studies, in which chitosan inhibited Aspergillus flavus growth (Cuero et al., 
1991a,b; Cuero et al. 1992), and also in in vitro studies of F. acuminatum and Cylindrocladium 
floridanum, which were completely inhibited (Laflamme et al., 2000). 
Rabea et al. (2003) has suggested that chitosan within the molecular weight range of 
10,000-100,000 kDa is ideal for restraining bacterial growth. Other research suggests chitosan 
within the molecular weight range of 200,000-300,000 kDa has shown higher efficacy against 
Gram-negative and Gram-positive organisms (Kim et al., 2007). While no specific range has 
been declared more efficacious, it has been suggested that lower molecular weight chitosans are 
more inhibitory against microorganisms than higher molecular weight chitosans (Kim et al., 
2006; Ganan et al., 2009). 
1.7.4 Application in poultry 
Many studies have been performed analyzing the inclusion of chitosan in poultry feed 
and the potential performance effects, with consistent results among the different studies. Studies 
have evaluated inclusion levels of chitosan in the poultry diet, indicating that a higher level of 
chitosan (3%) results in negative performance effects, including reduced live weight and feed 
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intake (Razdan and Pettersson, 1994; Razdan et al., 1997). Another evaluated lower levels of 
chitosan between 0.02 and 0.5% and determined that concentrations between 0.05 and 0.1% 
improved broiler performance in comparison to untreated birds (Shi et al., 2005). A study in 
which broiler treatment groups were fed chitosan salt, which constituted 3% of the poultry diet, 
resulted in slightly decreased weight gain of 2-2.5% compared to the control group (Balicka-
Ramisz et al., 2007). However, the results of this study showed birds treated with chitosan prior 
to exposure to S. gallinarum were highly resistant to S. gallinarum infection (Balicka-Ramisz et 
al., 2007), which may be considered as a potential trade-off in the poultry industry. Another 
study has evaluated the fat deposition and lipase effects of chitosan in broilers, concluding that 
dietary chitosan reduces excessive abdominal deposition, without sacrificing feed intake, body 
weight gain or feed efficiency (Kobayashi et al., 2002). A similar study evaluating dietary 
chitosan found body weight gain and feed intake were increased in birds fed chitosan compared 
to birds fed no chitosan, but that there were no differences in feed efficiency or breast meat or 
drumstick weight (Khambualai et al., 2009). Researchers’ consensus appears to conclude that 
lower inclusion levels of chitosan are not inhibitory to bird growth or performance.  
Chitosan presents potential for application in a processing plant as it has previously been 
applied in the food industry as an antimicrobial against a range of food-borne microorganisms 
(No et al., 2002; Sagoo et al., 2002; Beverlya et al., 2008). Chitosan has been applied as a spray 
product on fresh fruit, including tomatoes and strawberries, capable of extending shelf life of 
fresh foods (El Ghaouth et al., 1992a; El Ghaouth et al., 1992c). Menconi and colleagues (2013) 
evaluated the efficacy of 0.5% chitosan against Salmonella Typhimurium on dipped chicken 
skin. Chitosan effectively reduced Salmonella after 24 hours in one study, and then reduced 
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Salmonella to undetectable levels after 1 and 24 hours, and 3, 6, 9 and 12 days in a secondary 
study (Menconi et al., 2013).  
Chitosan may also have an application in poultry packaging. A study by Petrou and 
colleagues (2012) found chitosan combined with oregano oil added during packaging reduced 
mesophilic total plate counts, lactic acid bacteria, Brochothrix thermosphacta, 
Enterobacteriaceae, Pseudomonas spp., and yeast molds during the 21-day storage period. A 
chitosan-thyme combination was evaluated for efficacy against the same challenges mentioned 
in the previous study on packaged chicken kebabs, and chitosan-thyme significantly reduced 
total plate counts, lactic acid bacteria, Bronchotrhix thermosphacta, Enterobacteriacea, 
Pseudomonas spp., and yeast molds in comparison the controls after 12 days of storage 
(Giatrakou et al., 2010). A chitosan-arginine solution was tested on E. coli-inoculated chicken 
juice at varying doses (between 100-500 µg mL-1) to demonstrate potential application in poultry 
packaging (Lahmer et al., 2012). Results showed significant reduction of E. coli by treatments 
200 µg mL-1 and greater between 3-72 hours incubation (Lahmer et al., 2012).  
Reductions of other bacteria in vivo and post-harvest, combined with previous research 
indicating that lower levels of chitosan would not inhibit growth performance in broilers, make 
chitosan an ideal potential intervention strategy for Campylobacter research. Previously 
performed research indicates potential for chitosan as a pre-harvest intervention strategy in 
poultry feed, as well as a post-harvest strategy applied in the processing plant or poultry product 
packaging.  
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ABSTRACT 
Worldwide, Campylobacter is one of the leading causes of foodborne bacterial 
gastroenteritis causing an estimated 1.3 million infections in the United States alone. 
Consumption and/or cross-contamination of raw or undercooked poultry products have been 
linked as the most common source of Campylobacter infection, making the poultry industry a 
target for Campylobacter reduction strategies. Campylobacter is prevalent in most poultry flocks 
in the United States, with as many as 90% of flocks Campylobacter-positive at the time of 
slaughter. It is estimated that a reduction of Campylobacter in poultry would greatly reduce the 
risk of campylobacteriosis in humans. Unfortunately, there are a lack of effective intervention 
options to reduce Campylobacter in poultry.  One potential strategy is the use of the natural 
product, chitosan, a deacetylated byproduct of crustacean shells, has been shown to reduce E. 
coli and Salmonella.  The purpose of this study was to determine the ability of chitosan to reduce 
enteric Campylobacter colonization in pre-harvest chickens and on post-harvest chicken skin 
samples.  In each of three trials, 100 birds were divided into 10 treatments (n=10) and were fed 
either 0% (controls), 0.25%, 0.5% or 1% (wt./wt.) of a low, medium or high molecular weight 
chitosan (300 birds total). Birds were fed treated feed for the duration of the study and were 
orally challenged with a four-strain mixture of wild type C. jejuni on day 6. On day 15, the ceca 
were excised and enumerated for Campylobacter. In all three trials, the 0.5% dose of the medium 
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molecular weight chitosan reduced cecal Campylobacter counts. Because this medium molecular 
weight chitosan was shown to be the most effective, it was evaluated for post-harvest efficacy 
against Campylobacter on chicken skin.  When a 0.5, 1 or 2% concentration was tested in three 
separate trials, Campylobacter counts were not reduced when compared to controls.  These 
results support the use of chitosan in pre-harvest chickens but not for the reduction of 
Campylobacter as a post-harvest rinse on skin for the concentrations used in this study.  
Keywords: Campylobacter jejuni, chitosan, broiler, pre-harvest, post-harvest 
INTRODUCTION 
 Worldwide, Campylobacter is one of the most frequently reported food-borne pathogens 
and causes an estimated 1.3 million infections in the United States annually (CDC 2013a). 
Seasonal variation of campylobacteriosis occurs in some developed countries, generally peaking 
in the summer and fall (Nylen et al., 1992; Willis and Murray, 1997; Altekruse et al., 1999). 
However, this is not the case in many developing countries where Campylobacter infections 
consistently appear year-round (Taylor 1992; Oberhelman and Taylor, 2000). While the majority 
of Campylobacter cases result in acute gastroenteritis, infection has also been associated with 
more severe diseases, including Guillain-Barré syndrome (Goodyear et al., 1999; CDC, 2013b), 
reactive arthritis (ReA) (Berden et al., 1979; Ajene et al, 2013), irritable bowel syndrome (IBS) 
(NDDIC, 2013), and inflammatory bowel disease (IBD) (CDC, 2014). Epidemiological evidence 
supports the most common source for Campylobacter infections in humans is due to 
consumption of poultry products (Beery et al., 1988; Tauxe, 1997; CDC, 2013a). This is 
typically due to the consumption of improperly cooked chicken or cross-contamination from 
handling raw chicken (Danis et al., 2009; Fajó-Pascual et al. 2010; CDC, 2013a). Campylobacter 
colonization in poultry is common; for example, as many as 90% of U.S. broiler flocks are 
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contaminated with this food-borne pathogen (Buzby et al. 1997; Stern et al., 2001). In addition, 
because pre-harvest intervention strategies have not yet been successful in reducing 
Campylobacter, this bacterium is present and cross-contaminates the processing plant, between 
carcasses and equipment (Hargis et al., 1995; Zhang et al., 2013). Therefore, a reduction or 
elimination of Campylobacter in pre- and post-harvest poultry is a research priority to reduce the 
burden of this pathogen in humans.  
 Many pre-harvest strategies have been evaluated in an attempt to reduce Campylobacter 
in poultry, including biosecurity, probiotics, competitive exclusion, bacteriocins, bacteriophages, 
vaccines, and natural compounds, often with limited success (Mead, 2002; Cole et al., 2006; 
Santos et al., 2008a,b; Newell et al., 2011; Murali et al., 2012; Orquera et al., 2012; Saxena et al., 
2013). Recently, the natural product chitosan has shown potential to reduce colonization of 
another food-borne pathogen, Salmonella Typhimurium, in pre-harvest poultry (Menconi, et al. 
2013) and may have application against Campylobacter. Chitosan has also shown efficacy 
against other Gram-negative species, including Escherichia coli and Pseudomonas fluorescens, 
(No, et al., 2002; Rabea, et al. 2003). Chitosan, a natural byproduct, derived from the 
deacetylation of chitin, which is produced from crab and shrimp shell waste (No and Meyers, 
1995; No, et al. 2007). Chitosan is a potential natural food preservative, with broad antimicrobial 
benefits (No, et al. 2002; Sagoo, et al. 2002; Beverlya, et al. 2008). Although the exact mode of 
action of chitosan is unknown, researchers have previously determined that chitosan is capable of 
interacting with the outer cell membrane, altering its permeability (Helander, et al., 2001; Rabea, 
et al. 2003). To our knowledge, the ability of chitosan to reduce Campylobacter colonization in 
poultry has not been evaluated.  The purpose of this study was to determine the efficacy of 
chitosan on Campylobacter colonization in broiler chicks and as a post-harvest intervention 
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applied on chicken skin. Young chickens were used in this study because previous results from 
our laboratory demonstrated that young birds can be used as a reliable model to study 
Campylobacter colonization in market age birds (Solis de los Santos, et al. 2008a; Solis de los 
Santos, et al. 2009). 
MATERIALS AND METHODS 
Chitosan Materials 
 Chitosan of molecular weight 50-190 kDa and 190-310 kDa was obtained from Sigma-
Aldrich (St. Louis, MO), and 400-600 kDa chitosan was purchased from Spectrum Chemicals 
(New Brunswick, NJ). 
In vitro susceptibility of C. jejuni to chitosan 
 Antimicrobial activity of each molecular weight chitosan, low (50-190 kDa), medium 
(190-310 kDa) and high (400-600 kDa), in a 0.5% (wt./vol.) solution was determined by 
inoculating each solution with a four-strain mixture of wild-type Campylobacter jejuni.  
Preparation of the Campylobacter inoculum was done as described previously by Farnell and 
others (2005).  In brief, working stock cultures of the four wild-type strains of C. jejuni were 
obtained by individually inoculating each strain into fresh Campylobacter Enrichment Broth 
(CEB) from frozen glycerol stock and successively sub-culturing twice at 42°C for 48 hours 
under microaerophilic conditions.  Strain mixtures were then combined centrifuged at 3000 x g 
for 10 minutes and the cell pellet re-suspended in 10 mL Butterfield’s Phosphate Diluent (BPD).  
A 1% stock solution (wt./vol.) of each molecular weight of chitosan was prepared in 50 mM 
acetic acid as described by Ganan and others (2009).  For the experiment, the stock concentration 
of each of the chitosan solutions and the acetic acid control was diluted 1:1 with an inoculum 
containing 108 CFU/mL of C. jejuni, resulting in a final concentration of 0.5% for each chitosan.  
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Sample time points included 0, 2, 4 and 8 hours post-inoculation.  At each time point an aliquot 
from the treatments and control was taken and 1:10 serial dilutions were direct plated on Campy 
Line Agar (Line, 2001). The plates were incubated for 48 hours at 42°C in a microaerophilic 
atmosphere. Direct enumeration of Campylobacter colonies was converted to CFU/mL for each 
treatment.  Each susceptibility assay was repeated in duplicate. 
In vivo susceptibility of C. jejuni to chitosan 
 Day of hatch Cobb broiler chicks (Siloam Springs, AR) from a local commercial hatchery 
were utilized for the animal experiments. In each of three replicate trials, 100 chicks per trial 
were randomly divided into 10 treatments, which consisted of three concentrations (0.25%, 
0.5%, or 1% wt./wt.) of each molecular weight chitosan, which was added to the feed and a 
positive control (0% chitosan).  Birds were placed in floor pens and provided feed and water ad 
libitum; treated feed was provided throughout the entire trial. 
 The Campylobacter challenge was prepared with the same method as mentioned 
previously for in vitro susceptibility. Birds were challenged by oral gavage with 0.25 mL of a 
four strain mixture of wild-type Campylobacter jejuni on day 6, at a concentration of 107-108 
CFU/mL. On day 15, birds were euthanized and the ceca were excised for Campylobacter 
enumeration.  Cecal contents were serially diluted 10-fold with BPD and plated on CLA for 
direct enumeration. Plates were incubated at 42°C under microaerophilic conditions for 48 hours 
and enumerated for Campylobacter colonies as previously described by our laboratory (Aguiar et 
al., 2013). 
Post-harvest susceptibility of C. jejuni to chitosan 
For each experiment, skin from commercially available chicken thighs was cut into 2.0 g 
pieces (±.05g). A total of 40 skin samples were divided into 4 treatments (n=10/treatment), 
28 
which consisted of three concentrations (0.5%, 1%, or 2% wt./vol.) of medium molecular weight 
chitosan made soluble in 50 mM acetic acid and a positive control (50 mM acetic acid). The 
Campylobacter challenge was prepared as mentioned previously. Each piece of skin was 
inoculated individually with 50 µL of the 4 strain Campylobacter jejuni mixture (approximately  
108 CFU/mL). The Campylobacter was allowed to adhere to the skin for 30 minutes at room 
temperature prior to application of the treatments. Per each treatment group, skin samples were 
simultaneously dipped into each treatment for 30 seconds, removed and allowed to air dry for 2 
minutes. Samples were then transferred individually to conical tubes, serially diluted, plated on 
Campy Line Agar (Line, 2001) and incubated for 48 hours at 42°C in a microaerophilic 
atmosphere as described above.  Direct enumeration of Campylobacter colonies was converted 
to CFU/mL of treatment.  The trial was repeated in triplicate. 
Statistical analysis 
 Cecal and skin Campylobacter jejuni counts were logarithmically transformed before 
analysis to achieve homogeneity of variance (Byrd et al., 2003). Analysis of the data was done 
using the PROC GLM procedure of SAS (SAS Institute, 2002).  Treatment means were 
partitioned by LSMEANS analysis (SAS Institute, 2002) and probability of P < 0.05 was 
required for statistical significance.  
RESULTS 
Chitosan in vitro 
 Campylobacter counts were reduced by approximately 1 log at 2 and 4 hour when co-
incubated with 0.5% for all three molecular weights of chitosan when compared with controls 
(Table 1). At 8 hours, all three chitosan preparations produced a 4½ to 5 log reduction in counts 
when compared with controls.  
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Chitosan in vivo 
 In trial 1, Campylobacter counts were reduced in six of the chitosan treatments: 0.25% 
and 0.5% LMW, 0.25% and 0.5% MMW, 0.25% and 1% HMW, in comparison to the positive 
control (Table 2). Trial 2 showed significant reduction of Campylobacter by four of the chitosan 
treatments: 0.5% LMW, 1% LMW, 0.25% MMW, and 0.5% MMW (Table 2). Results from 
Trial 3 showed significant reduction of Campylobacter by one of the chitosan treatments: 0.5% 
MMW (Table 2).  
Chitosan post-harvest 
  Campylobacter counts were not reduced by 0.5%, 1% or 2% chitosan treatments applied 
to the skin for any of the three studies (Table 3). In trials 1 and 2, there were no differences 
between the four treatments; however, in the trial 3, there were higher Campylobacter counts 
from the skin treated with 2% medium molecular weight chitosan, in comparison to the positive 
control, 0.5% or 1% medium molecular weight. 
DISCUSSION 
 Preliminary in vitro results utilizing a 0.5% dose demonstrate that the three molecular 
weight chitosan treatments reduce Campylobacter counts in comparison to the untreated controls 
(Table 1). To evaluate the ability of chitosan to reduce enteric Campylobacter colonization in 
chickens, the 0.5% concentration of all three molecular weight chitosans, plus a lower (0.25%) 
and higher dose (1%) was also evaluated.  In the first trial, cecal Campylobacter counts were 
reduced in 6 out of 8 of the treatments (Table 2).  When conducted in a second trial, 4 of the 8 
treatments were effective whereas in a third replicate trial, the 0.5% MMW reduced enteric 
Campylobacter counts when compared with controls (Table 2).   Although there is variability 
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among replicate trials, the 0.5% MMW chitosan dose consistently reduced Campylobacter in all 
three trials.  
The significance of replicating results demonstrating a significant reduction in enteric 
Campylobacter counts in pre-harvest poultry cannot be underestimated.  Previous research 
conducted by our laboratory (Solis de los Santos et al., 2008; Metcalf et al., 2011) and others 
(Hakkinen and Schneitz, 1999; Hilmarsson et al., 2006; Robyn et al., 2013) have highlighted the 
variability among trials when evaluating pre-harvest treatments against enteric Campylobacter. 
Because of this inherent variability associated with Campylobacter colonization studies, results 
from a single preharvest study may not fully evaluate the consistency, or ruggedness of a 
Campylobacter intervention strategy (Carvalho et al., 2010; Molatová et al., 2010; Van Deun et 
al., 2010; Neal-McKinney et al., 2012).  
Although the 0.5% dose of the MMW chitosan was effective in consistently reducing 
Campylobacter counts in pre-harvest chickens (Table 2), it was not effective when applied to 
processed skin samples (Table 3).  In fact, Campylobacter counts were actually higher in one of 
the trials utilizing the 2% dose.  The inability of chitosan to be effective on chicken skin may be 
due to its viscosity in solution, especially at higher concentrations.  Chitosan appears to coat 
chicken skin possibility preventing the removal of loosely adhering Campylobacter cells from 
the skin surface.  Therefore, it may not be a suitable post-harvest treatment in poultry processing 
plants. 
Feed application of chitosan is a viable application for reducing Campylobacter 
colonization in chickens, however, water application is also a possible option.  Unfortunately, 
chitosan is insoluble in water within the normal pH range (Chandumpai et al., 2004; Qin et al., 
2004).  This problem can be resolved by mildly acidifying the water, as accomplished in our in 
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vitro and post-harvest skin trials.  It is possible this will enhance the efficacy of this compound as 
proposed by Qin and co-workers (2006).  Acidifying water lines is already being performed in 
some poultry operations and is reported to reduce another foodborne pathogen, Salmonella (Byrd 
et al., 2003), and may also aid in the reduction of Campylobacter in the water lines and during 
feed withdrawal prior to processing, without altering the gut epithelium (Byrd et al., 2001; 
Chaveerach et al., 2004). Thus, acidifying water in poultry houses could have a number of 
positive effects on bird health and reduce the potential zoonotic transfer of pathogens to humans.  
This possibility is currently under investigation.  
The use of pre-harvest intervention strategies to reduce Campylobacter colonization (e.g., 
chitosan) can be part of a multifaceted approach to reduce the incidence of this foodborne 
pathogen.  It has been proposed that a 2-log reduction in Campylobacter on the chicken carcass 
could reduce the risk of human campylobacteriosis by up to 30-fold (Rosenquist, et al. 2003). 
Perceivably “small” reductions of Campylobacter in chickens could result in large reductions of 
campylobacteriosis incidences in humans. Olsen and colleagues (2008) compiled data relevant to 
the consistent rise of campylobacteriosis incidences from the 1980s through 2006 in many 
countries, including Denmark, England, Wales, Norway, Sweden, New Zealand, and Australia, 
many of which are currently monitored by the ECDC. In the 2000s, New Zealand focused on 
poultry as the primary source of Campylobacter and applying required regulatory 
implementations, along with the assistance of voluntary interventions, New Zealand saw a 54% 
decline in campylobacteriosis incidences in 2008 compared to the 2002-2006 years (Sears, et al. 
2011).  This decline was associated with only a relatively small reduction of approximately ½- 
log Campylobacter counts on chicken carcasses (French, 2010). New Zealand’s well-
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documented reduction of campylobacteriosis cases sets precedence for global reduction of 
Campylobacter by focusing intervention strategies on the poultry industry. 
In conclusion, enteric Campylobacter counts were consistently reduced for the 0.5% 
MMW chitosan in three replicate trials but this treatment was not effective on post-harvest skin 
samples.  The use of this chitosan in pre-harvest poultry may be incorporated into a multifaceted 
strategy to reduce Campylobacter counts in chickens.   
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Table 1: The effect of different molecular weight chitosans on in vitro growth of Campylobacter 
jejuni 1, 2, 3 
 
Campylobacter counts, in vitro 
  Hours 
Treatment 0 2 4 8 
Positive controls 6.35 x 107 8.15x107 5.45x107 3.5x107 
Low Molecular Weight 3.42x107 6.8x106 1.24x106 3.0x102 
Medium Molecular Weight 8.55x107 2.55x106 1.82x106 5.5x102 
High Molecular Weight 7.45x107 2.59x106 2.00x106 6.5x102  
10.5% concentration of: low molecular weight chitosan is 50-190 kDa; medium molecular weight 
chitosan is 190-310 kDa; or high molecular weight chitosan is 400-600 kDa, in 50 mM acetic 
acid 
2Campylobacter inoculum was added to each chitosan treatment and then sampled at 0, 2, 4, and 
8 hours; samples were plated and enumerated after 48 hour incubation 
3Values represent average campylobacteriosis counts of two separate replicate trials 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
34 
Table 2: The effect of different concentrations and molecular weight chitosans on cecal 
Campylobacter jejuni counts (means±SEM) in 15-day old broiler chicks during three separate 
trials 1, 2, 3, 4 
 
Campylobacter counts, in vivo 
 Chitosan 
dose 
Trial 1 Trial 2 Trial 3 
Positive controls 
 
0% 8.77±.17a 7.05±.69a 8.36±.24a 
Low Molecular Weight 
.25% 7.06±.58cde 7.1±.29ab 8.59±.20a 
.5% 7.68±.27bcd 3.96±1.02c 7.88±.38ab 
1% 7.96±.15abc NDd 7.76±.40ab 
Medium Molecular Weight 
.25% 6.76±.34de 4.83±1.08bc 8.47±.21a 
.5% 7.4±.38bcd 3.25±.94c 7.28±.70b 
1% 8.03±.14abc 7.45±.34a 8.57±.17a 
High Molecular Weight 
.25% 7.45±.19bcd 7.49±.31a 8.16±.29ab 
.5% 8.43±.18ab 7.8±.35a 8.34±.26a 
1% 6.3±.74e 7.31±.30a 8.51±.19a 
 
1Low molecular weight chitosan is 50-190 kDa; medium molecular weight chitosan is 190-310 
kDa; high molecular weight chitosan is 400-600 kDa 
2ND= non-detectible 
3Day-of-hatch birds were fed chick starter treatments of 0.25%, 0.5% or 1% of either low 
molecular weight, medium molecular weight or high molecular weight chitosan, respectively, for 
the entire 15-day study; bird were inoculated with Campylobacter jejuni mixture on day 6 and 
cecal contents were collected on Day 15 for campylobacteriosis enumeration 
4Means within columns with no common superscript differ significantly (p<.05) 
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Table 3: The effect of different concentrations of medium molecular weight chitosan on skin 
Campylobacter jejuni counts (means±SEM) in vitro 1, 2, 3 
 
Campylobacter counts on skin 
Treatment Trial 1 Trial 2 Trial 3 
Positive controls (0% chitosan) 3.78±.44a 4.94±.68a 2.75±.41b 
0.5% Medium Molecular Weight 3.93±.44a 3.79±.53a 2.40±.48b 
1% Medium Molecular Weight 3.78±.37a 4.93±.22a 2.20±.42b 
2% Medium Molecular Weight 4.27±.13a 5.16±.19a 3.97±.15a 
 
1Medium molecular weight chitosan is 190-310 kDa 
2Campylobacter inoculum was added to each skin sample, allowed to adhere for 30 minutes, and 
then skin samples were dipped into the respective solutions; samples were plated and enumerated 
after 48 hour incubation 
3Means within columns with no common superscript differ significantly (p<.05) 
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